BIOTECHNOLOGY VALUE FUND
Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of its investments. BVF is committed to working with its portfolio companies as partners in their successes.
BIOTECHNOLOGY VALUE FUND
Industry:
Biotechnology Venture Capital
Founded:
1993-01-01
Status:
Active
Contact:
(312)506-6479
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress PHP PHP 7 Twemoji OpenResty
Similar Organizations
Atlas Venture
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Azure Capital Partners
Azure Capital Partners is a venture capital firm specializing in early-stage and growth capital investments.
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-19 | Kymera Therapeutics | Biotechnology Value Fund investment in Post-IPO Equity - Kymera Therapeutics | 150 M USD |
| 2021-07-13 | Nimbus Therapeutics | Biotechnology Value Fund investment in Venture Round - Nimbus Therapeutics | 105 M USD |
| 2021-04-08 | Ventus Therapeutics | Biotechnology Value Fund investment in Series B - Ventus Therapeutics | 100 M USD |
| 2021-03-30 | Pyxis Oncology | Biotechnology Value Fund investment in Series B - Pyxis Oncology | 152 M USD |
| 2020-12-28 | Gritstone Bio | Biotechnology Value Fund investment in Post-IPO Equity - Gritstone Bio | 125 M USD |
| 2020-07-22 | Olema Oncology | Biotechnology Value Fund investment in Series B - Olema Oncology | 54 M USD |
| 2020-06-11 | Autobahn Therapeutics | Biotechnology Value Fund investment in Series B - Autobahn Therapeutics | 76 M USD |
| 2020-05-20 | Surface Oncology | Biotechnology Value Fund investment in Post-IPO Equity - Surface Oncology | 28.9 M USD |
| 2020-03-12 | Kymera Therapeutics | Biotechnology Value Fund investment in Series C - Kymera Therapeutics | 102 M USD |
| 2020-01-31 | Syndax Pharmaceuticals | Biotechnology Value Fund investment in Post-IPO Debt - Syndax Pharmaceuticals | 30 M USD |